ArticleBrain and behavior2026
Glymphatic System Dysfunction and its Associated Factors in Wilson's Disease: A DTI-ALPS Study.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWilson's disease (WD) is a genetic disorder of copper (Cu) metabolism that causes Cu accumulation in multiple organs, particularly the liver and brain, resulting in progressive multisystem damage. This study investigated glymphatic system function and its associated factors in patients with WD.
methodsSeventy-one patients with WD (19 hepatic, 52 neurological) and 15 healthy controls (HCs) were enrolled. The analysis along the perivascular space (ALPS) index was quantified using diffusion tensor imaging (DTI-ALPS). Comparisons were performed between patients and than HCs, and across WD phenotypes, and correlations with clinical characteristics were analyzed.
resultsCompared with HCs, patients with WD exhibited significantly reduced ALPS index (p < 0.001). Patients with neurological WD had a significantly lower ALPS index than those with hepatic WD (p = 0.018) and HCs (p < 0.001). No significant difference was observed between patients with hepatic WD and HCs (p = 0.077). In neurological WD, the ALPS index was significantly higher on the left side than that on the right (p < 0.001), whereas no significant interhemispheric differences were found in hepatic WD or HCs (p > 0.05). In neurological WD, the ALPS index correlated positively with albumin, fasting blood glucose, and the white matter volume-to-total intracranial volume ratio (V_WM/TIV ratio), and negatively with age, alanine aminotransferase, aspartate aminotransferase (AST), and the unified WD rating scale-part I (UWDRS-I) score. Multiple regression identified age, AST, and the UWDRS-I score as independent predictors of reduced ALPS index.
conclusionsNeurological WD was associated with impaired glymphatic system function and altered lateralization. Age, AST, and the UWDRS-I score were independently associated with dysfunction.Glymphatic function, assessed by DTI-ALPS index, was impaired in neurological WD compared with the hepatic phenotype and controls. Age, AST, and UWDRS-I score independently predicted dysfunction, linking neurodegeneration, liver injury, and altered glymphatic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.